In this study, an ORR of 83.3%, DCR of 100% and median PFS of 8.3 months were observed in Cohort A (driver gene negative, treat-naïve NSCLC patients tested positive for EGFR protein). Here, EGFR is linked to non-small cell lung carcinoma.